<SEC-DOCUMENT>0001193125-17-022637.txt : 20170130
<SEC-HEADER>0001193125-17-022637.hdr.sgml : 20170130
<ACCEPTANCE-DATETIME>20170130081932
ACCESSION NUMBER:		0001193125-17-022637
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170127
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170130
DATE AS OF CHANGE:		20170130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		17555416

	BUSINESS ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d332940d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): January&nbsp;27, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MICROBOT MEDICAL INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-19871</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94-3078125</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>175 Derby Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Hingham, MA 02043 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (908)&nbsp;938-5561 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or Former Address, if Changed Since Last Report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Entry into a Material Definitive Agreement </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;27, 2017, Microbot Medical
Inc. (the &#147;Company&#148;) entered into a Contract Research Agreement (the &#147;Agreement&#148;) with The Washington University (&#147;Washington U.&#148;), pursuant to which the parties will collaborate to determine the effectiveness of the
Company&#146;s self-cleaning shunt, a device designed to prevent obstruction in the cerebrospinal fluid catheters implanted in the ventricle of the brain of patients who suffer from hydrocephalus and Normal Pressure Hydrocephalus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial research to be performed by Washington U. is expected to be completed within 6 months, with a comprehensive study to follow and be
completed in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of these studies, to be paid by the Company, is expected to be approximately $130,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Agreement, all rights, title and interest in the data, information and results obtained or arrived at by Washington U. in the
performance of its services under the Agreement, as well as any patentable inventions obtained or arrived at in the performance of such services, will be jointly owned by the Company and Washington U., and each will have full right to practice and
grant licenses in joint inventions. Additionally, Washington U. granted to the Company (a)&nbsp;a non-exclusive, worldwide, royalty-free, fully paid-up, perpetual and irrevocable license to use and practice patentable inventions (other than joint
inventions and improvements to Washington U.&#146;s animal models) obtained or arrived at by Washington U. in the provision of its services under the Agreement (&#147;University Inventions&#148;) with respect to the self-cleaning shunt and
(b)&nbsp;an exclusive option to obtain an exclusive worldwide license in University Inventions, on terms to be negotiated between the parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agreement contains customary confidentiality provisions and an indemnity in favor of Washington U. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agreement shall continue for a period of two years, subject to early termination for breach or if the principal investigators at
Washington U. cease to supervise the services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms of the Agreement is subject to, and qualified in its
entirety by, the full text of the Agreement, which will be filed with the Company&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2016. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;30, 2017, the Company issued a press release announcing
the execution of the Agreement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated January 30, 2017</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MICROBOT MEDICAL INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harel Gadot</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Harel Gadot</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chairman, President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: January&nbsp;30, 2017 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d332940dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g332940micro.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Microbot Medical Inc. Announces Research Collaboration Agreement with Washington University School of
Medicine, a Leading Academic Institution to Evaluate a Revolutionary Self-Cleaning Shunt Device Designed to Prevent Obstruction in Cerebrospinal Fluid Catheters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Studies to be Administered by Recognized Experts in the Field of Hydrocephalus </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company Expects the Studies to be Completed in 2018 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hingham, MA &#150; January&nbsp;30, 2017 &#150; Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development
of transformational micro-robotic medical technologies, announced today that it has entered into a research collaboration agreement with Washington University School of Medicine, a leading academic institution based in St. Louis, MO to determine the
safety and effectiveness of the Microbot Medical self-cleaning shunt (SCS), a device which is designed to prevent obstruction in the cerebrospinal fluid (CSF) catheters implanted in the ventricle of the brain of patients who suffer from
hydrocephalus or Normal Pressure Hydrocephalus (NPH). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hydrocephalus is a condition which causes an excessive accumulation of fluid in the brain and
effects one out of every 500 infants born in the United States alone every year while NPH is a condition that typically develops over time and effects the elderly population. The primary objective of these pre-clinical studies is to determine the
safety and effectiveness of the Company&#146;s SCS device to prevent obstruction in CSF catheters in clinically relevant in vivo studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal
investigators (PI) for the studies are James Patterson McAllister, PhD, a Professor of Neurology at Washington University School of Medicine and St. Louis Children&#146;s Hospital, and David D. Limbrick, Jr., MD, PhD, Professor and Chief of
Pediatric Neurosurgery at St. Louis Children&#146;s Hospital. Dr.&nbsp;McAllister is a leading authority in the field of research aimed at identifying clinical treatments for hydrocephalus, and for the last 30 years his laboratory has maintained a
comprehensive interdisciplinary translational research program whose ultimate goal is to improve clinical treatments for hydrocephalus. Dr. Limbrick focuses on treating children with neurological diseases, including hydrocephalus, and he has been
recognized on&nbsp;<I>The Best Doctors in America</I>&nbsp;list. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I can attest to the fact that surgical interventions for the treatment of hydrocephalus have not improved
outcomes as much as expected and the major obstacle to progress is the failure to prevent shunt obstruction. The studies we will be conducting with Microbot Medical are specifically intended to develop and test new approaches to solve this
problem,&#148; commented Dr.&nbsp;McAllister. &#147;Our research group at Washington University is well positioned to partner with Microbot Medical in this endeavor as we have become one of the main hydrocephalus clinical and experimental research
centers in the world.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently, Carolyn Harris, PhD at Wayne State University (WSU) in Detroit, will run an in vitro study of the
Company&#146;s SCS device. The main objective of this study is to test and finalize the design of Microbot&#146;s SCS, using Dr.&nbsp;Harris&#146; bio-reactor system that mimics human brain tissue three-dimensionally. Dr.&nbsp;Harris is nationally
and internationally recognized as an expert in hydrocephalus due to her comprehension of the pathophysiology of the disorder and her investigation into shunt obstruction and shunt infection utilizing unique model systems. The Harris laboratory
studies hydrocephalus with a prudent focus on bioengineering strategies that could improve treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This is an exciting development milestone in
continuing our efforts and progression to validate the safety and effectiveness of our self-cleaning shunt device,&#148; commented Harel Gadot, CEO, President and Chairman. &#147;We are addressing a large unmet need in this market and our
collaboration with these leading academic institutions will allow us to validate our technology, and as such will allow us to transform any technology currently on the market, a market which really has not seen any major advancements since the
1950&#146;s. The study is being administered by some of the leading hydrocephalus clinicians and scientists in the world and we look forward to sharing the findings as we seek to improve and extend the quality of life for those suffering from
hydrocephalus and normal pressure hydrocephalus.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Microbot Medical, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Microbot was founded in 2010 and became a NASDAQ listed company on November&nbsp;28, 2016. The Company specializes in transformational micro-robotic medical
technologies leveraging the natural and artificial lumens within the human body. Microbot&#146;s current platforms, ViRob and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its
first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy
procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or
within the body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight
spaces and curved passages as well as the ability to remain within the human body for prolonged time. To learn more about ViRob please visit http://www.microbotmedical.com/technology/virob/. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TipCAT is a transformational self-propelled, flexible, and semi-disposable endoscope providing see&nbsp;&amp; treat capabilities within tubular lumens in the
human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable to navigate and crawl through natural&nbsp;&amp; artificial tubular lumens, applying the minimal necessary pressure to achieve the
adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT visit http://www.microbotmedical.com/technology/tipcat/. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Washington University School of Medicine </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington University School of Medicine&#146;s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis
Children&#146;s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News&nbsp;&amp; World Report. Through its affiliations with
Barnes-Jewish and St. Louis Children&#146;s hospitals, the School of Medicine is linked to BJC HealthCare. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as &#147;will,&#148; &#147;believes,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;expects&#148; and &#147;estimates&#148;) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the businesses of Microbot Medical Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.&#146;s filings with the Securities and Exchange Commission. Microbot Medical
disclaims any intent or obligation to update these forward-looking statements. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EVC Group </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Polyviou/Doug Sherk - Investors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mpolyviou@evcgroup.com; dsherk@evcgroup.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">212-850-6020;
415-652-9100 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g332940micro.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332940micro.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MP5*4Z3Y9JQ9K4S/*/'O_ ",\O_7-/Y52 V_AC_QXZC_UW_I28'>4@"@ H *
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MOO%44R*3#9J6=NVX]!0P&>,/^1IO?]X?R%,1V'PV_P"1:?\ Z[O_ #J1G8T
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M =YX%.?"%EC_ &__ $(T@.CH * "@ H * "@ H * "@ H * "@ H * "@ H
M* *T.G65M+++!:PQO+_K&5 "WU]: &PZ986\$L$-G#'%+]]%0 -]10 Z/3K.
M*T-I':Q+;MUB"#:?PH @M-#TNPF,UII\$,G]Y4 - #KW1]-U%U>\L8)W7HSH
M": '0Z5I]O(TD-E!&[+M8K& 2/0T /MK"SLXGBMK6*&-^65$ !^HH KV^A:5
M:70N;?3[>*<='5 "* %N-#TNZN1<W&GV\DX.=[1@F@!Z:1IT<4L26,"QS?ZQ
M1& &^HH L6]M#:0K#;Q)%$O1$& * ): "@ H * "@ H * "@ H * "@ H *
?"@ H * "@ H * "@ H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
